Kiadis and Hospira terminate the deal which grants Hospira rights to ATIR for Graft versus host disease (GvHD) in Europe, Japan, the Middle East, Africa, Australia, and parts of Asia

Kiadis Pharma N.V.

the Netherlands / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Hospira Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated